Cargando…
Empagliflozin—A New Chance for Patients with Chronic Heart Failure
The heart failure (HF) epidemic is one of the challenges that has been faced by the healthcare system worldwide for almost 25 years. With an ageing world population and a fast-paced lifestyle that promotes the development of cardiovascular disease, the number of people suffering from heart failure w...
Autores principales: | Kowalska, Klaudia, Walczak, Justyna, Femlak, Joanna, Młynarska, Ewelina, Franczyk, Beata, Rysz, Jacek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779904/ https://www.ncbi.nlm.nih.gov/pubmed/35056104 http://dx.doi.org/10.3390/ph15010047 |
Ejemplares similares
-
New Insights into the Use of Empagliflozin—A Comprehensive Review
por: Forycka, Joanna, et al.
Publicado: (2022) -
Chronic Kidney Disease as a Comorbidity in Heart Failure
por: Szlagor, Magdalena, et al.
Publicado: (2023) -
The Influence of SARS-CoV-2 Infection on Lipid Metabolism—The Potential Use of Lipid-Lowering Agents in COVID-19 Management
por: Kowalska, Klaudia, et al.
Publicado: (2022) -
The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy
por: Kowalska, Klaudia, et al.
Publicado: (2022) -
New Insights into Molecular Mechanisms of Chronic Kidney Disease
por: Frąk, Weronika, et al.
Publicado: (2022)